Seattle Genetics' stock falls despite panel recommendation

Seattle Genetics' stock price fell to $19.17 in pre-market trading despite yesterday's expert panel recommendation accelerated approval of the company's drug, brentuximab vedotin (Adcetris). Investors are apparently concerned that the FDA may ask for more data about the drug's benefits given the fact that the developer only conducted two small trials for the blood cancer drug. The developer's stock dropped to $18.81 after the market opened. Story

Suggested Articles

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.

Less than two years after taking the reins from founding chief Rusty Williams, Five Prime Therapeutics CEO Aron Knickerbocker is exiting the company.